

# Kenichi Nakamura

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8873059/publications.pdf>

Version: 2024-02-01

13  
papers

1,751  
citations

1162889

8  
h-index

1125617

13  
g-index

13  
all docs

13  
docs citations

13  
times ranked

1458  
citing authors

#	ARTICLE	IF	CITATIONS
1	Survey Results and Recommendations from Japanese Stakeholders for Good Clinical Practice Renovation. <i>Therapeutic Innovation and Regulatory Science</i> , 2022, 56, 220-229.	0.8	1
2	Overview of the ethical guidelines for medical and biological research involving human subjects in Japan. <i>Japanese Journal of Clinical Oncology</i> , 2022, 52, 539-544.	0.6	56
3	Posttherapy topographical nodal status, ypN-site, predicts survival of patients who received neoadjuvant chemotherapy followed by curative surgical resection for non-type 4 locally advanced gastric cancer: supplementary analysis of JCOG1004-A. <i>Gastric Cancer</i> , 2021, 24, 197-204.	2.7	5
4	Gastrectomy with or without neoadjuvant S-1 plus cisplatin for type 4 or large type 3 gastric cancer (JCOG0501): an open-label, phase 3, randomized controlled trial. <i>Gastric Cancer</i> , 2021, 24, 492-502.	2.7	79
5	Regulatory and operational challenges in conducting Asian International Academic Trial for expanding the indications of cancer drugs. <i>Clinical and Translational Science</i> , 2021, 14, 1015-1025.	1.5	2
6	Regulatory changes after the enforcement of the new Clinical Trials Act in Japan. <i>Japanese Journal of Clinical Oncology</i> , 2020, 50, 399-404.	0.6	26
7	Recommendations for promoting international multi-site clinical trials” from a viewpoint of ethics review. <i>Developing World Bioethics</i> , 2019, 19, 192-195.	0.6	1
8	Determination of the optimal cutoff percentage of residual tumors to define the pathological response rate for gastric cancer treated with preoperative therapy (JCOG1004-A). <i>Gastric Cancer</i> , 2015, 18, 597-604.	2.7	29
9	A randomized Phase II trial of systemic chemotherapy with and without trastuzumab followed by surgery in HER2-positive advanced gastric or esophagogastric junction adenocarcinoma with extensive lymph node metastasis: Japan Clinical Oncology Group study JCOG1301 (Trigger Study). <i>Japanese Journal of Clinical Oncology</i> , 2015, 45, 1082-1086.	0.6	38
10	Phase II study of preoperative chemotherapy with S-1 and cisplatin followed by gastrectomy for clinically resectable type 4 and large type 3 gastric cancers (JCOG0210). <i>Journal of Surgical Oncology</i> , 2013, 107, 741-745.	0.8	98
11	Three-arm Phase III Trial Comparing Cisplatin Plus 5-FU (CF) Versus Docetaxel, Cisplatin Plus 5-FU (DCF) Versus Radiotherapy with CF (CF-RT) as Preoperative Therapy for Locally Advanced Esophageal Cancer (JCOG1109, NExT Study). <i>Japanese Journal of Clinical Oncology</i> , 2013, 43, 752-755.	0.6	257
12	Evaluation of Three Definitions of Progression-free Survival in Preoperative Cancer Therapy (JCOG0801-A). <i>Japanese Journal of Clinical Oncology</i> , 2012, 42, 896-902.	0.6	7
13	A Randomized Trial Comparing Postoperative Adjuvant Chemotherapy with Cisplatin and 5-Fluorouracil Versus Preoperative Chemotherapy for Localized Advanced Squamous Cell Carcinoma of the Thoracic Esophagus (JCOG9907). <i>Annals of Surgical Oncology</i> , 2012, 19, 68-74.	0.7	1,152